Jeong Tae-Dong, Park Chan-Jeoung, Shim Hyoeun, Jang Seongsoo, Chi Hyun-Sook, Yoon Dok Hyun, Kim Dae-Young, Lee Jung-Hee, Lee Je-Hwan, Suh Cheolwon, Lee Kyoo Hyung
Department of Laboratory Medicine, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea.
Korean J Hematol. 2012 Dec;47(4):260-6. doi: 10.5045/kjh.2012.47.4.260. Epub 2012 Dec 24.
Flow cytometric immunophenotyping has been used to identify neoplastic plasma cell populations in patients with multiple myeloma (MM). Previous reports have described the use of several antigens, including CD38, CD138, CD56, CD117, CD52, CD19 and CD45, to distinguish distinct populations of plasma cells. The aim of this study was to evaluate a simplified immunophenotyping panel for MM analysis.
A total of 70 patients were enrolled in the study, 62 of which were newly diagnosed with MM (untreated), whereas the remaining 8 were undergoing bone marrow assessment as part of follow-up after treatment (treated). Treated cases included 3 patients with relapse and 5 patients with persistence of MM. Multiparametric flow cytometric immunophenotyping was performed using monoclonal antibodies against CD56, CD19, CD138 (CD38), and CD45.
In differential counts, plasma cells in bone marrow (BM) accounted for 3.6-93.2% of the total nucleated cell count. The positive expression rates of CD56, CD19, CD138, and CD45 in neoplastic myeloma cells were 83.9%, 0%, 98.4%, and 37.1%, respectively, among the 62 untreated cases, and 75.0%, 0%, 87.5%, and 37.5%, respectively, among the 8 treated cases. CD19 expression of neoplastic plasma cells was negative in both untreated and treated cases.
The simplified immunophenotyping panel, CD56/CD19/CD138(CD38)/CD45, is useful for distinguishing neoplastic myeloma cells from reactive plasma cells in clinical practice. In addition, CD19 represents the most valuable antigen for identifying neoplastic myeloma cells in patients with MM.
流式细胞术免疫表型分析已用于识别多发性骨髓瘤（MM）患者的肿瘤性浆细胞群体。既往报道描述了使用几种抗原，包括CD38、CD138、CD56、CD117、CD52、CD19和CD45，来区分不同的浆细胞群体。本研究的目的是评估一种用于MM分析的简化免疫表型分析组合。
本研究共纳入70例患者，其中62例为新诊断的MM（未治疗），其余8例在治疗后作为随访的一部分进行骨髓评估（已治疗）。已治疗的病例包括3例复发患者和5例MM持续存在患者。使用抗CD56、CD19、CD138（CD38）和CD45的单克隆抗体进行多参数流式细胞术免疫表型分析。
在分类计数中，骨髓（BM）中的浆细胞占总核细胞计数的3.6% - 93.2%。在62例未治疗的病例中，肿瘤性骨髓瘤细胞中CD56、CD19、CD138和CD45的阳性表达率分别为83.9%、0%、98.4%和37.1%，在8例已治疗的病例中分别为75.0%、0%、87.5%和37.5%。肿瘤性浆细胞的CD19表达在未治疗和已治疗的病例中均为阴性。
简化的免疫表型分析组合CD56/CD19/CD138（CD38）/CD45在临床实践中有助于区分肿瘤性骨髓瘤细胞和反应性浆细胞。此外，CD19是识别MM患者肿瘤性骨髓瘤细胞最有价值的抗原。
